2012 2011 2010 2009 
2008
| 2008 |
Ghosh AK, Chapsal BD, Baldridge A, Ide K, Koh Y, and Mitsuya H. Design and synthesis of stereochemically defined novel spirocyclic P2-ligands for HIV-1 protease inhibitors. Org Lett. 10(22):5135-5138, 2008. |
||
 |
||
Ghosh AK, Gemma S, Baldridge A, Wang YF, Kovalevsky AY, Koh Y, Weber IT, and Mitsuya H. Potent HIV-1 Protease Inhibitors Incorporating meso-Bicyclic Urethanes as P2-ligands: Structure-Based Design, Synthesis, Biological Evaluation and Protein-Ligand X-Ray Studies. Org Biomol Chem. 6(20):3703-3713, 2008. |
||
|
||
| Ghosh AK, Gemma S, Baldridge A, Leshchenk S, Wang YF, Kovalevsky AY, Koh Y, Weber IT, and Mitsuya H. Flexible cyclic ethers/polyethers as novel P2-ligands for HIV-1 protease inhibitors: design, synthesis, biological evaluation, and protein-ligand X-ray studies. J Med Chem. 51(19):6021-6033, 2008. | ||
|
||
| Maeda K, Das D, Yin PD, Tsuchiya K, Ogata-Aoki H, Nakata H, Norman RB, Hackney LA, Takaoka Y, and Mitsuya H. Involvement of the second extracellular loop and transmembrane residues of CCR5 in inhibitor binding and HIV-1 fusion: insights into the mechanism of allosteric inhibition. J Mol Biol. 381(4):956-974, 2008. | ||
|
||
Kawamoto A, Kodama E, Sarafianos SG, Sakagami Y, Kohgo S, Kitano K, Ashida N, Iwai Y, Hayakawa H, Nakata H, Mitsuya H, Arnold E, and Matsuoka M. 2'-deoxy-4'-C-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variants. Int J Biochem Cell Biol. 40(11):2410-2420, 2008. |
||
|
||
| Nakata H, Steinberg SM, Koh Y, Maeda K, Takaoka Y, Tamamura H, Fujii N, and Mitsuya H. Potent synergistic anti-human immunodeficiency virus (HIV) effects using combinations of the CCR5 inhibitor aplaviroc with other anti-HIV drugs. Antimicrob Agents Chemother. 52(6): 2111-2119, 2008. | ||
|
||
| Mitsuya H, Maeda K, Das D, and Ghosh AK. Development of protease inhibitors and the fight with drug-resistant HIV-1 variants. Adv Pharmacol. 56:169-197, 2008. | ||
|
||
Ghosh AK, Chapsal BD, Weber IT, and Mitsuya H. Design of HIV Protease Inhibitors Targeting Protein Backbone: An Effective Strategy for Combating Drug Resistance. Acc Chem Res. 41(1):78-86, 2008. |
||
|
||
Kitano M, Kobayashi N, Kawashima Y, Akahoshi T, Nokihara K, Oka S, and Takighuchi M. Identification and characterization of HLA-B*5401-restricted HIV-1-Nef and Pol-specific CTL epitopes. Microbes Infect. 10(7):764-772, 2008. |
||
|
||
| Tanuma J, Fujiwara M, Teruya K, Matsuoka S, Yamanaka H, Gatanaga H, Tachikawa N, Kikuchi Y, Takiguchi M, and Oka S. HLA-A*2402-restricted HIV-1-specific cytotoxic T lymphocytes and escape mutation after ART with structured treatment interruptions. Microbes Infect. 10(6):689-698, 2008. | ||
|
||
| Tsukamoto T, Dohki S, Ueno T, Kawada M, Takeda A, Yasunami M, Naruse T, Kimura A, Takiguchi M* and Matano T* (*equally contribution). Determination of a major histocompatibility complex class I restricting simian immunodeficiency virus Gag241-249 epitope. AIDS. 22(8):993-994, 2008. | ||
|
||
Hachiya A, Kodama EN, Sarafianos SG, Schuckmann MM, Sakagami Y, Matsuoka M, Takiguchi M, Gatanaga H, and Oka S. Amino Acid Mutation N348I in the Connection Subdomain of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confers Multiclass Resistance to Nucleoside and Nonnucleoside Reverse Transcriptase Inhibitors. J Virol. 82(7):3261-3270, 2008. |
||
|
||
| Ueno T, Motozono C, Douki S, Mwimanzi P, Rauch S, Fackler OT, Oka S, and Takiguchi M. CTL-mediated selective pressure influences dynamic evolution and pathogenic functions of HIV-1 Nef. J Immunol. 180(2):1107-1116, 2008. | ||
|
||
Kawashima Y, Satoh M, Oka S, Shirasaka T, and Takiguchi M. Different immunodominance of HIV-1-specific CTL epitopes among three subtypes of HLA-A*26 associated with slow progression to AIDS. Biochem Biophys Res Commun. 366(3):612-616, 2008. |
||
|
||
 |
Fujiwara M, Tanuma J, Koizumi H, Kawashima Y, Honda K, Mastuoka-Aizawa S, Dohki S, Oka S, and Takiguchi M. Different Abilities of Escape Mutant-Specific Cytotoxic T Cells to Suppress Replication of Escape Mutant and Wild-type HIV-1 in New Hosts. J Virol. 82(1):138-147, 2008. | |
|
||
|
Maeda Y, Yusa K, and Harada S. Altered sensitivity of an R5X4 HIV-1 strain 89.6 to coreceptor inhibitors by a single amino acid substitution in the V3 region of gp120. Antiviral Res. 77(2):128-135, 2008. | |
|
||
|
Harada S, Monde K, Tanaka Y, Kimura T, Maeda Y, and Yusa K. Neutralizing antibodies decrease the envelope fluidity of HIV-1. Virology. 370(1):142-150, 2008. | |
|
||
|
Ryo A, Tsurutani N, Ohba K, Kimura R, Komano J, Nishi M, Soeda H, Hattori S, Perrem K, Yamamoto M, Chiba J, Mimaya J, Yoshimura K, Matsushita S, Honda M, Yoshimura A, Sawasaki T, Aoki I, Morikawa Y, and Yamamoto N. SOCS1 is an inducible host factor during HIV-1 infection and regulates the intracellular trafficking and stability of HIV-1 Gag. Proc Natl Acad Sci U S A. 105(1):294-299, 2008. | |
|
||
|
Hayashida T, Gatanaga H, Tanuma J, and Oka S. Effect of low HIV type 1 load and antiretroviral treatment on IgG-capture BED-enzyme immunoassay. AIDS Res Hum Retroviruses. 24(3):495-498, 2008. |
|
|
||
|
Murakami T, Harada H, Suico MA, Shuto T, Suzu S, Kai H, and Okada S. Ephedrae herba, a component of Japanese herbal medicine Mao-to, efficiently activates the replication of latent human immunodeficiency virus type 1 (HIV-1) in a monocytic cell line. Biol Pharm Bull. 31(12):2334-2337, 2008. | |
|
||
|
Okada S, Harada H, Ito T, Saito T, and Suzu S. Early development of human hematopoietic and acquired immune systems in new born NOD/Scid/Jak3null mice engrafted with cord blood-derived CD34+ cells. Int J Hematol. 88(5):476-482, 2008. |
|
|
||
|
Ikeda T, Ohsugi T, Kimura T, Matsushita S, Maeda Y, Harada S, and Koito A. The anti-retroviral potency of APOBEC1 deaminase from small animal species. Nucleic Acids Res. 36(21):6859-6871, 2008. | |
 |
 |